natgillin/translations-raw huggingface dataset:
Clear Type I glass vial with a latex-free bromobutyl rubber stopper and aluminium over-seal, containing 50 ml of concentrate for solution for infusion.
Viala iz prozornega stekla tipa I z zamaškom iz brombutilne gume brez lateksa in s prekrivno zaporo iz aluminija; viala vsebuje 50 ml koncentrata za raztopino za infundiranje.
Clear type I glass vials closed by a grey butyl or black chlorobutyl rubber stopper covered with a crimped-on aluminium ring and a cap.
Viale iz prozornega stekla tipa I, ki so zaprte s sivim butilnim ali črnim klorobutilnim gumastim zamaškom, zavarovanim z aluminijastim objemnim obročkom in zaporko.
Clear yellow gel.
Prozoren, rumen gel
Clear yellow solution
Prozorna rumena raztopina.
Clear yellow solution for injection.
Prozorna rumena raztopina za injiciranje.
Clear yellow solution.
Prozorna, rumena raztopina.
Clear yellow to brownish solution.
Bistra, rumena do rjavkasta raztopina
Clear yellow viscous liquid.
Prozorna rumena viskozna tekočina.
Clear, colorless 10 ml type I glass vial with chlorobutyl rubber stopper and aluminium crimp cap with a flip- off cap, containing 100 mg of pemetrexed.
Prozorne, brezbarvne 10 ml viale iz stekla tipa I z gumijasto zaporko iz klorobutila in aluminijasto zaporko, ki vsebuje 100 mg pemetrekseda.
Clear, colorless 100 ml type I glass vial with chlorobutyl rubber stopper and aluminium crimp cap with a flip-off cap, containing 1000 mg of pemetrexed.
Prozorne, brezbarvne 100 ml viale iz stekla tipa I z gumijasto zaporko iz klorobutila in aluminijasto zaporko, ki vsebuje 1000 mg pemetrekseda.
Clear, colorless 50 ml type I glass vial with chlorobutyl rubber stopper and aluminium crimp cap with a flip- off cap, containing 500 mg of pemetrexed.
Prozorne, brezbarvne 50 ml viale iz stekla tipa I z gumijasto zaporko iz klorobutila in aluminjasto zaporko, ki vsebuje 500 mg pemetrekseda.
Clear, colourless and waterlike.
Bistra, brezbarvna, podobna vodi.
Clear, colourless isotonic solution with pH between 6.0 and 8.0.
bistra, brezbarvna izotonična raztopina s pH med 6,0 in 8,0
Clear, colourless or almost colourless, isotonic solution; pH=8.15.
Bistra, brezbarvna ali skoraj brezbarvna, izotonična raztopina s pH 8,15.
Clear, colourless solution, free of particulate matter.
Bistra, brezbarvna raztopina brez trdnih delcev.
Clear, colourless solution.
bistra brezbarvna raztopina za injiciranje
Clear, colourless solution.
Raztopina je bistra, brezbarvna in vodi podobne konsistence.
Clear, colourless solution.
Raztopina je bistra, brezbarvna.
Clear, colourless to light yellow liquid solution.
Bistra, brezbarvna do rumenkasta tekočina.
Clear, colourless to pale yellow aqueous solution.
bistra, brezbarvna do bledo rumena vodna raztopina
Clear, colourless to pale yellow in colour.
Bistra, brezbarvna do bledo rumena.
Clear, colourless to pale yellow liquid.
bistra, brezbarvna do bledo rumena tekočina.
Clear, colourless to pale yellow solution
Bistra brezbarvna do bledorumena raztopina.
Clear, colourless to pale yellow solution
Bistra, brezbarvna do bledorumena raztopina.
Clear, colourless to pale yellow solution.
bistra brezbarvna do bledo rumena raztopina
Clear, colourless to pale yellow solution. pH: 6.0 – 7.5
Bistra, brezbarvna do bledo rumena raztopina. pH: 6,0–7,5
Clear, colourless to slightly yellow solution.
Prozorna, brezbarvna do nekoliko rumenkasta raztopina.
Clear, colourless to slightly yellow, solution with a pH: 6.3 ±0.3.
Bistra, brezbarvna do rahlo rumenkasta raztopina s pH: 6,3 ± 0,3.
Clear, colourless to yellowish solution.
Prozorna brezbarvna do rumenkasta raztopina.
Clear, colourless, neutral solution.
Bistra, brezbarvna, nevtralna raztopina.
Clear, colourless-to-white solution for injection that may contain some product-related translucent-to- white amorphous particles.
Bistra, brezbarvna do bela raztopina za injiciranje, ki lahko vsebuje nekaj prosojnih do belih amorfnih delcev.
Clear, to slightly opalescent, colourless solution.
Bistra do rahlo opalescentna brezbarvna raztopina
Clear, Type I, flint glass, single-use vial, grey butyl rubber stopper, and aluminium overseal with flip- off-cap.
Viala za enkratno uporabo iz prozornega kristalnega stekla vrste I z zamaškom iz sive butilne gume in aluminijasto zapiralno obrobo z zaporko.
Clear, yellowish orange to pink colored suspension for injection.
Bistra, rumeno-oranžna do rožnato obarvana suspenzija za injiciranje
Clear/minimal
čisto/minimalno
Clearance (dL/(kg.hr))
Očistek (dl/(kg.h))
Clearance (mL/h/kg)
Očistek (ml/h/kg)
Clearance (ml/kg*h)
Očistek (ml/kg*h)
Clearance and volume of distribution at steady state are comparable between healthy subjects and patients with infections.
Očistek in volumen porazdelitve v stanju dinamičnega ravnovesja sta primerljiva med zdravimi osebami in pacienti z okužbo.
Clearance c, L/h/kg
Očistek c, l/h/kg
Clearance following subcutaneous dosing was estimated to be 21.0 ml/h in a rheumatoid arthritis population pharmacokinetic analysis, with an inter-subject variability of 30.8% (CV) and an inter- occasion variability of 22.0%.
Očistek po subkutanem odmerjanju je bil v populacijski farmakokinetični analizi bolnikov z revmatoidnim artritisom ocenjen na 21,0 ml/h s 30,8 % variabilnostjo med preiskovanci (CV) in 22,0 % variabilnostjo med poskusi.
Clearance is about 0.1 l/h/kg, and terminal half-life (t1/2) about 1 h.
Očistek je približno 0,1 l/h/kg, končni razpolovni čas (t1/2) pa približno 1 ura.
Clearance is about 15-20 l/h and independent of dose.
Očistek je približno 15–20 l/h in je neodvisen od odmerka.
Clearance is decreased after repeated administration of stiripentol, probably due to inhibition of the cytochrome P450 isoenzymes responsible for its metabolism.
Očistek se zmanjša po ponavljajočem dajanju stiripentola, verjetno zaradi zaviranja izoencimov citokroma P450, ki so odgovorni za presnovo stiripentola.
Clearance may be reduced in patients with low creatinine clearance.
Očistek je lahko zmanjšan pri bolnikih z nizkim očistkom kreatinina.
Clearance of cinacalcet is higher in smokers than in non-smokers, likely due to induction of CYP1A2- mediated metabolism.
Očistek cinakalceta je pri kadilcih večji kot pri nekadilcih, verjetno zaradi indukcije presnove s CYP1A2.
Clearance of dabigatran in patients with renal insufficiency may take longer.
Pri bolnikih z ledvično insuficienco je lahko čas očistka dabigatrana iz plazme podaljšan.
Clearance of HCV may lead to increased replication of HBV in patients who are HCV/HBV co-infected.
Odpravljanje okužbe s HCV lahko pri bolnikih, ki so sočasno okuženi s HCV/HBV, privede do večjega podvojevanja HBV.
Clearance of tolvaptan is not significantly affected by age.
Starost nima pomembnega vpliva na očistek tolvaptana.
Clearance values of Soliris in paediatric aHUS patients were 10.4, 5.3, and 2.2 mL/hr with body weight of 70, 30, and 10 kg, respectively; and the corresponding volume of distribution values were 5.23, 2.76, and 1.21 L, respectively.
Vrednosti očistka zdravila Soliris pri pediatričnih bolnikih z aHUS so bile 10,4; 5,3 oziroma 2,2 ml/h pri telesni masi 70, 30 oziroma 10 kg; ustrezne vrednosti porazdelitvenega prostora pa so bile 5,23; 2,76 oziroma 1,21 l.
Clearance was 0.0145 L/h with a range of 0.00904 – 0.0229 for no increase in anti-pegloticase antibodies and 0.0193 L/h with a range of 0.00675 – 0.0340 for an increase in anti-pegloticase antibodies.
Očistek pri odsotnosti povečanja protiteles proti peglotikazi je bil 0,0145 l/h z razponom 0,00904–0,0229, pri povečanju ravni protiteles proti peglotikazi pa 0,0193 l/h z razponom 0,00675–0,0340.
Clearance was dose- and time-independent.
Vrednost očistka je bila odvisna od višine danega odmerka in se je spreminjala s časom.
Clearance was not affected by age (range 23-88 years), gender, concomitant use of budesonide or dacarbazine, performance status, HLA-A2*0201 status, mild hepatic impairment, renal impairment, immunogenicity, and previous anticancer therapy.
Starost (razpon od 23 do 88 let), spol, sočasna uporaba budezonida ali dakarbazina, stanje telesne zmogljivosti, status HLA-A2*0201, blaga okvara jeter, okvara ledvic, imunogenost in predhodno zdravljenje raka niso vplivali na očistek.
Clearance, weight-normalised clearance, and AUC were not appreciably different among patients with different body weights, including those weighing ≥125 kg.
Očistek, na telesno maso normalizirani očistek in AUC, se med bolniki z različno telesno maso, tudi pri tistih, ki so tehtali 1 125 kg, niso znatno razlikovali.
clearance.
Če očistek kreatinina
Clearance: 0.665 ± 0.0493 l/h (Mean ± SE)
Očistek: 0,665 ± 0,0493 l/h (povprečje ± SE)
Cleared from plasma (days)***
Izčistek iz plazme (dnevi)
cleared primarily by
CYP3A/2C19 z
cleft lip, cardiovascular malformations and neural tube defects.
Najpogostejše okvare so razcepljena ustnica, kardiovaskularne malformacije in okvare nevralne cevi.
CLEOPATRA (WO20698) is a multicentre, randomised, double-blind, placebo-controlled phase III clinical trial conducted in 808 patients with HER2-positive metastatic or locally recurrent unresectable breast cancer.
CLEOPATRA (WO20698) je multicentrična, randomizirana, dvojno slepa, s placebom kontrolirana klinična študija faze III, v katero je bilo vključenih 808 bolnikov s HER2 pozitivnim metastatskim rakom dojk ali z lokalno neoperabilno ponovitvijo raka dojk.
Click 10 seconds Keep holding the clear base firmly against your skin.
Klik 10 sekund Še naprej trdno držite prozorno podnožje na koži.
Clicking Starts
Klikanje se začne
clicks
2,1
clicks
2,7
clicks
3,3
clicks
3,6
clicks
3,9
clicks
klikov
clicks
klikov 6
clicks
klikov 7
clicks
klikov 8
clicks
klikov 9
clicks
polna obrata
clicks
polni obrati
Clincal cases consistent with an increase in docetaxel toxicity were reported when it was combined with ritonavir.
Med uporabo docetaksela skupaj z ritonavirjem so bili opisani klinični primeri, ki se skladajo s povečano toksičnostjo docetaksela.
CLINCAL PARTICULARS
KLINIČNI PODATKI
Clinic SBP: LS Mean Change from Baseline (BL) to Week 6 (mm Hg) (LOCF)
Klinični SKT: Povprečna sprememba NK od izhodišča do 6. tedna (mm Hg) (ZOPN)
Clinical
Klinični del
Clinical and biological surveillance when antithrombin is used together with heparin, low molecular weight heparin or other anticoagulants which potentiate the anticoagulant activity of antithrombin:
Potreben je klinični in biološki nadzor, ko se antitrombin uporablja skupaj s heparinom, heparinom z nizko molekularno maso ali drugimi antikoagulanti, ki okrepijo antikoagulantno aktivnost antitrombina:
Clinical and laboratory
priporočeno klinično in laboratorijsko
Clinical and surveillance data: Natural mutations associated with reduced susceptibility to oseltamivir in vitro have been detected in influenza A and B viruses isolated from patients without exposure to oseltamivir.
Klinični podatki in podatki pridobljeni s spremljanjem zdravila po prihodu na trg: pri virusih gripe A in B, izoliranih iz bolnikov, ki niso bili izpostavljeni oseltamivirju, so in vitro odkrili naravne mutacije, povezane z zmanjšano občutljivostjo za oseltamivir.
Clinical aspects:
Klinični vidiki:
Clinical Benefit Rate (CBR)
Delež klinične koristi (DKK)
Clinical Benefit Rate (ORR+MR) [n(%)]
stopnja dosežene klinične koristi (ORR+MR) [n(%)]
Clinical benefit ratec
delež bolnic s klinično koristjoc
Clinical Breakpoints S ≤ 0.25 mg/l; R > 0.25 mg/l
0,25 mg/l klinična mejna vrednost S  0,25 mg/l; R> 0,25 mg/l
Clinical cases of hypothyroidism have been reported in thyroidectomy patients undergoing levothyroxine replacement during treatment with imatinib (see section 4.5).
Pri bolnikih, ki so med zdravljenjem z zdravilom Imatinib Actavis prejemali nadomestno zdravljenje z levotiroksinom po tiroidektomiji, so poročali o kliničnih primerih hipotiroidizma (glejte poglavje 4.5).
Clinical characteristics of never smoker, adenocarcinoma histology, and female gender have been shown to be independent predictors of positive EGFR mutation status in a multivariate analysis of 786 Caucasian patients from gefitinib studies* (see Table 7).
Klinične značilnosti, da oseba ni nikdar kadila, da ima histologijo adenokarcinoma in da je ženskega spola, so bile neodvisni napovedniki pozitivnega stanja mutacije EGFR v multivariatni analizi 786 bolnikov-belcev v študijah gefitiniba* (glejte preglednico 7).
Clinical chemistry evaluations revealed biologically relevant significant increases in the mean BUN and alkaline phosphatase values in females after the 28-day treatment.
Klinično-kemični podatki so pokazali biološko relevantno povečanje srednje vrednosti BUN-a ter vrednosti alkalne fosfataze pri ženskah po 28 dnevnem zdravljenju.
Clinical chemistry tests, which include liver function tests, should be performed prior to initiating nevirapine therapy and at appropriate intervals during therapy.
Klinične kemijske preglede, ki zajemajo jetrne preiskave, je treba opraviti pred začetkom zdravljenja z nevirapinom in v ustreznih razmikih med zdravljenjem.
Clinical Comments
(0,83-0,94)
Clinical Comments
(0,92-1,10)
Clinical Comments
0,57 (0,48-0,67)
Clinical Comments
0,92 (0,76-1,12)
Clinical Comments
icer ni treba
Clinical Comments
natančno klinično
Clinical Comments
ombitasvirjem
Clinical Comments
prilagoditi.
Clinical Comments
revir/ritonavir ni
Clinical Comments
Če je klinično
Clinical Complete Response (CCR) %
Celotni klinični odziv (CCR)
Clinical Cure, mITT Population
Klinična ozdravitev, populacija mITT
Clinical data (semen analyses and inhibin B levels – [a glycoprotein produced by Sertoli cells – used as a surrogate marker of testicular function]) showed no evidence of altered testicular function.
Klinični podatki (analiza semenske tekočine in koncentracija inhibina B [glikoproteina, ki nastaja v Sertolijevih celicah in se uporablja kot nadomestni označevalec delovanja mod]) niso pokazali znakov spremenjenega delovanja mod.
Clinical data are not yet available in this population (see section 4.2).
Za to populacijo klinični podatki še niso na voljo (glejte poglavje 4.2).
Clinical data confirm that CYP3A4 is responsible for the N- dealkylation of buprenorphine.
Klinični podatki potrjujejo, da je za N-dealkilacijo buprenorfina odgovoren CYP3A4.
Clinical data described below suggest that the risk for clinically meaningful interactions by co- administered medicinal products is low.
Navedeni klinični podatki kažejo na majhno tveganje klinično pomembnih interakcij s sočasno danimi zdravili.
Clinical data described below suggest that the risk for clinically meaningful interactions by co- administered medicinal products is low.
Spodaj opisani klinični podatki kažejo, da je tveganje za klinično pomembne interakcije pri sočasni uporabi drugih zdravil majhno.
Clinical data described below suggest that the risk for clinically meaningful interactions by co-administered medicinal products is low.
Spodaj opisani klinični podatki kažejo, da je tveganje za klinično pomembne interakcije pri sočasni uporabi drugih zdravil majhno.
Clinical data described below suggest that the risk for clinically meaningful interactions by coadministered medicinal products is low.
Navedeni klinični podatki kažejo na majhno tveganje klinično pomembnih interakcij s sočasno danimi zdravili.
Clinical data from trials in other patient populations
Klinični podatki iz preskušanj z drugimi skupinami bolnikov
Clinical data have demonstrated that there is no interaction between ceftazidime and avibactam, and between ceftazidime/avibactam and metronidazole.
Klinični podatki so pokazali, da med ceftazidimom in avibaktamom ter med kombinacijo ceftazidim/avibaktam in metronidazolom ni medsebojnih delovanj.
Clinical data in children less than 6 years of age who received two doses of Pandemic influenza vaccine H5N1, indicate an increase in frequency of fever (axillary≥38°C) after the administration of the second dose.
Klinični podatki otrok, mlajših od 6 let, ki so prejeli dva odmerka cepiva proti pandemski gripi H5N1, kažejo večjo pogostnost zvišane telesne temperature (aksilarno ≥ 38 °C) po uporabi drugega odmerka.
Clinical data in paediatric patients has demonstrated that patients receiving r-HuEPO two or three times weekly may be converted to once weekly Aranesp, and those receiving r-HuEPO once weekly may be converted to once every other week Aranesp.
Klinični podatki pri pediatričnih bolnikih kažejo, da lahko tisti, ki dobivajo r-HuEPO dva- ali trikrat na teden, preidejo na zdravilo Aranesp enkrat na teden, tisti, ki dobivajo r-HuEPO enkrat na teden, pa na zdravilo Aranesp enkrat vsak drugi teden.
Clinical data in renal cell carcinoma
Klinični podatki pri karcinomu ledvičnih celic
Clinical data indicate that regorafenib has no effect on digoxin pharmacokinetics, therefore can be given concomitantly with p-glycoprotein substrates, such as digoxin, without a clinically meaningful drug interaction.
Klinični podatki kažejo, da regorafenib ne vpliva na farmakokinetiko digoksina, zato se ga lahko daje sočasno s substrati glikoproteina P, kot je digoksin, ne da bi prišlo do klinično pomembnega medsebojnega delovanja.
Clinical data is very limited (n = 3) for CML patients with moderate renal impairment receiving an escalated dose of 600 mg bosutinib.
Klinični podatki pri bolnikih s KML z zmerno okvaro ledvic, ki prejemajo povečan odmerek 600 mg bosutiniba, so zelo omejeni (n = 3).
Clinical data obtained from a limited number of patients also indicate that adult PID patients may tolerate an infusion rate of up to 8 ml/kg BW/hr.
Klinični podatki, dobljeni pri omejenem številu bolnikov, kažejo tudi, da lahko odrasli bolniki s primarno imunsko pomanjkljivostjo prenašajo hitrost infundiranja do 8 ml/kg TM na uro.
Clinical data on treatment in immunocompromised patients is not available, but systemic risks are not expected since ingenol mebutate is not absorbed systemically.
Klinični podatki o zdravljenju pri imunokomprimiranih bolnikih niso na voljo, vendar ni pričakovati sistemskih tveganj, saj se ingenol mebutat ne absorbira sistemsko.
Clinical data suggest that hepatic fat accumulation is reversible after stopping treatment with Lojuxta, but whether histological sequelae remain is unknown, especially after long-term use.
Klinični podatki kažejo, da je kopičenje maščob v jetrih reverzibilno po prekinitvi zdravljenja z zdravilom Lojuxta, vendar ni znano, ali ima histološke posledice, predvsem po dolgotrajni uporabi.
Clinical data were collected for 30 days of treatment.
Klinične podatke so zbirali 30 dni zdravljenja.
Clinical Description of abacavir HSR
Klinični opis HSR na abakavir
Clinical drug-drug interaction studies with dalbavancin have not been conducted.
Klinične zdravilo-zdravilo študije interakcij z dalbavancinom niso bile izvedene.
Clinical efficacy
Stabilna bolezen (%)
Clinical efficacy and in-vivo recovery of Nuwiq was not affected in this patient.
Klinična učinkovitost ter in vivo uporabnost zdravila Nuwiq pri tem bolniku nista bili prizadeti.
Clinical efficacy and safety
Kliničn učinkovitost in varnost
Clinical efficacy and safety
Klinična učinkovitost in varnost Velike depresivne motnje:
Clinical efficacy and safety
Klinična učinkovitost in varnost:
Clinical efficacy and safety
Klinične študije
Clinical efficacy and safety
Klnična učinkovitost in varnost
Clinical efficacy and safety
Posebna opozorila in previdnostni ukrepi
Clinical efficacy and safety (DVT/PE prevention)
Klinična učinkovitost in varnost (preprečevanje GVT/PE)
Clinical efficacy and safety (DVT/PE treatment)
Klinična učinkovitost in varnost (zdravljenje GVT/PE)
Clinical efficacy and safety (SPAF)
Klinična varnost in učinkovitost (SPAF)
Clinical efficacy and safety in Parkinson’s disease
Klinična učinkovitost in varnost pri Parkinsonovi bolezni
Clinical efficacy and safety in Restless Legs Syndrome
Klinična učinkovitost in varnost pri sindromu nemirnih nog
Clinical efficacy and safety in special populations
Klinična učinkovitost in varnost pri posebnih populacijah
Clinical efficacy and safety of Prograf capsules bid in primary organ transplantation
Objavljene študije o klinični učinkovitosti in varnosti kapsul Prograf pri primarnih presaditvah organov
Clinical efficacy and safety studies of Zavicefta have been conducted in cIAI and cUTI only.
Klinične študije učinkovitosti in varnosti zdravila Zavicefta so izvedli le pri cIAI in cUTI.
Clinical efficacy and safety Treatment-experienced adult patients Pivotal studies
Klinična učinkovitost in varnost Že zdravljeni odrasli bolniki Ključne študije
Clinical efficacy and safety – Adults
Klinična učinkovitost in varnost – odrasli
Clinical efficacy and safety – paediatric population
Klinična učinkovitost in varnost – pediatrična populacija
Clinical efficacy defined as partial or complete response, has been demonstrated for Aspergillus spp. including A. flavus, A. fumigatus, A. terreus, A. niger, A. nidulans; Candida spp., including C. albicans, C. glabrata, C. krusei, C. parapsilosis and C. tropicalis; and limited numbers of C. dubliniensis,
Klinična učinkovitost, opredeljena kot delni ali popolni odziv, je bila dokazana za Aspergillus spp., vključno z A. flavus, A. fumigatus, A. terreus, A. niger, A. nidulans, za Candida spp., vključno s C. albicans, C. glabrata, C. krusei, C. parapsilosis in C. tropicalis in omejenim številom C. dubliniensis,
Clinical efficacy has been demonstrated for the following Aspergillus species: Aspergillus fumigatus, flavus, A. niger, and A. terreus (see further below).
Klinična učinkovitost je bila dokazana za naslednje vrste gliv Aspergillus: Aspergillus fumigatus, A. flavus, A. niger, and A. terreus (glejte v nadaljevanju spodaj).
Clinical efficacy has been demonstrated for the following Aspergillus species: Aspergillus fumigatus, flavus, A. niger, and A. terreus(see further below).
Klinična učinkovitost je bila dokazana za naslednje vrste gliv Aspergillus: Aspergillus fumigatus, A. flavus, A. niger, and A. terreus (glejte v nadaljevanju).
Clinical efficacy has not been established against the following pathogens although in vitro studies suggest that they would be susceptible to oritavancin in the absence of acquired mechanisms of resistance:
Klinične učinkovitosti proti naslednjim patogenom niso ugotovili, čeprav študije in vitro nakazujejo, da bi lahko bili dovzetni za oritavancin v odsotnosti pridobljenih mehanizmov odpornosti:
Clinical efficacy has not been established against the following pathogens although in vitro studies suggest that they would be susceptible to Zerbaxa in the absence of acquired mechanisms of resistance:
Klinična učinkovitost proti naslednjim patogenom ni bila dokazana, čeprav študije in vitro nakazujejo, da so občutljivi na zdravilo Zerbaxa, če nimajo pridobljenih mehanizmov odpornosti:
Clinical efficacy in adults and skeletally mature adolescents with giant cell tumour of bone
Klinična učinkovitost pri odraslih in skeletno dozorelih mladostnikih z gigantocelularnim kostnim tumorjem
Clinical efficacy in homozygous familial hypercholesterolaemia
Klinična učinkovitost pri homozigotni družinski hiperholesterolemiji
Clinical efficacy in patients with bone metastases from solid tumours
Klinična učinkovitost pri bolnikih s kostnimi metastazami solidnih tumorjev
Clinical efficacy in previously untreated mantle cell lymphoma (MCL)
Klinična učinkovitost zdravila pri bolnikih s predhodno nezdravljenim limfomom plaščnih celic (MCL)
Clinical efficacy in previously untreated multiple myeloma
Klinična učinkovitost pri bolnikih s predhodno nezdravljenim diseminiranim plazmocitomom
Clinical efficacy in the treatment of Paget’s disease of the bone
Klinična učinkovitost pri zdravljenju Pagetove bolezni kosti
Clinical efficacy in women aged 15 to 25 years
Klinična učinkovitost pri ženskah starih med 15 in 25 let
Clinical efficacy in women aged 26 years and older
Klinična učinkovitost pri ženskah, starih 26 let in več
Clinical efficacy of Descovy in treatment-naïve patients was also established from a study conducted with emtricitabine and tenofovir alafenamide (10 mg) when given with darunavir (800 mg) and cobicistat as a fixed-dose combination tablet (D/C/F/TAF).
Klinično učinkovitost zdravila Descovy pri predhodno nezdravljenih bolnikih so dokazali tudi v študiji, opravljeni z emtricitabinom in alafenamidtenofoviratom (10 mg) v kombinaciji z darunavirjem (800 mg) in kobicistatom v obliki tablete s kombinacijo fiksnih odmerkov (D/C/F/TAF).